Beta Bionics recently brought its iLet bionic pancreas to market in 2023 and completed an IPO to become a publicly-traded ...

Beta Bionics Inc.’s concept of an artificial pancreas that regulates blood sugar levels in people with type 1 diabetes (T1D) ...

Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today ...

Abbott, Dexcom, Insulet, Medtronic and others are developing next-gen sensors, pumps and algorithms for type 2 diabetes ...

Expanding its portfolio, the company is introducing the Patch Pump and developing the bi-hormonal iLet while forging ...

Sales of Beta Bionics insulin pumps spiked 145% in the fourth quarter behind solid new patient starts. Elsewhere, former ...

Beta Bionics ... an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin ...

(Nasdaq:BBNX) shares rose after hours today on fourth-quarter results that topped the consensus sales forecast.

Ladenburg analyst Jeffrey Cohen initiated coverage of Beta Bionics (BBNX) with a Buy rating and $31 price target The medical device company offers the iLet Bionic Pancreas, which is the first FDA ...

Beta Bionics completed pump compatibility testing and released ... released our first year of real-world evidence for the iLet, progressed in our efforts to secure pharmacy channel coverage ...